Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial
Zenas BioPharma, Inc. announced positive results from the Phase 2 MoonStone trial of obexelimab in Relapsing Multiple Sclerosis (RMS).
Obexelimab met its primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009.
Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009
Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to developing transformative therapies for patients with autoimmune diseases.
Author's summary: Zenas BioPharma reports positive results.
More News
- CRC Screening Improvements Decrease Mortality, but Disparities Persist
- 2 US Navy aircraft crash in South China Sea
- Staffordshire Leader Reacts to "Squandered" Billions of Taxpayers' Money on Asylum Hotels - Staffordshire County Council Newsroom
- Managing Benign Prostatic Hyperplasia: Your BPH Treatment Options
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- BioDlink Biopharm Co., Ltd.: BioDlink Completes First International Shipment of Bevacizumab to Colombia
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow
- Deandre Ayton claims Los Angeles Lakers superstars ‘troll him’ to get him going
- Deadline is Dec. 31 to apply for Renew NC grants - Hendersonville Lightning
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?